388 related articles for article (PubMed ID: 21551161)
1. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
Funck-Brentano C; van Veldhuisen DJ; van de Ven LL; Follath F; Goulder M; Willenheimer R;
Eur J Heart Fail; 2011 Jul; 13(7):765-72. PubMed ID: 21551161
[TBL] [Abstract][Full Text] [Related]
2. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.
Willenheimer R; van Veldhuisen DJ; Silke B; Erdmann E; Follath F; Krum H; Ponikowski P; Skene A; van de Ven L; Verkenne P; Lechat P;
Circulation; 2005 Oct; 112(16):2426-35. PubMed ID: 16143696
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III.
Willenheimer R; Erdmann E; Follath F; Krum H; Ponikowski P; Silke B; Van Veldhuisen DJ; Van De Ven L; Verkenne P; Lechat P;
Eur J Heart Fail; 2004 Jun; 6(4):493-500. PubMed ID: 15182776
[TBL] [Abstract][Full Text] [Related]
4. Implications of CIBIS III: a commentary.
Willenheimer R
J Renin Angiotensin Aldosterone Syst; 2005 Dec; 6(3):115-20. PubMed ID: 16525941
[TBL] [Abstract][Full Text] [Related]
5. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure.
van de Ven LL; van Veldhuisen DJ; Goulder M; Zilahi Z; Meyer WR; Willenheimer R
Int J Cardiol; 2010 Sep; 144(1):59-63. PubMed ID: 19481278
[TBL] [Abstract][Full Text] [Related]
6. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II.
Krum H; Bailey M; Meyer W; Verkenne P; Dargie H; Lechat P; Anker S
Cardiology; 2007; 108(1):28-34. PubMed ID: 16960445
[TBL] [Abstract][Full Text] [Related]
7. Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.
Krum H; van Veldhuisen DJ; Funck-Brentano C; Vanoli E; Silke B; Erdmann E; Follath F; Ponikowski P; Goulder M; Meyer W; Lechat P; Willenheimer R;
Cardiovasc Ther; 2011 Apr; 29(2):89-98. PubMed ID: 20528880
[TBL] [Abstract][Full Text] [Related]
8. [Chronic heart failure and sudden death: the message of CIBIS-III].
Dequarti MC; Poggio L; Vanoli E
Recenti Prog Med; 2007 Dec; 98(12):638-45. PubMed ID: 18369041
[TBL] [Abstract][Full Text] [Related]
9. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial.
Dobre D; van Veldhuisen DJ; Goulder MA; Krum H; Willenheimer R
Cardiovasc Drugs Ther; 2008 Oct; 22(5):399-405. PubMed ID: 18528751
[TBL] [Abstract][Full Text] [Related]
11. [The use of beta blockers in heart failure: clinical studies].
Cobelli F
Ital Heart J Suppl; 2000 Aug; 1(8):996-1002. PubMed ID: 10993005
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
[TBL] [Abstract][Full Text] [Related]
13. [Beginning therapy of heart failure with beta blockers. Do these patients survive longer?].
MMW Fortschr Med; 2005 Sep; 147(39):10. PubMed ID: 16245769
[No Abstract] [Full Text] [Related]
14. Using Cardicor as first-line therapy in heart failure : CiBis iii.
Cardiovasc J Afr; 2009; 20(1):78. PubMed ID: 19382368
[No Abstract] [Full Text] [Related]
15. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ
Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
17. Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee.
Fundam Clin Pharmacol; 1997; 11(2):138-42. PubMed ID: 9107560
[TBL] [Abstract][Full Text] [Related]
18. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
[TBL] [Abstract][Full Text] [Related]
19. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy.
Gosse P; Roudaut R; Herrero G; Dallocchio M
J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S145-50. PubMed ID: 11527119
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
